Alla studier
RekryteringFAS3INTERVENTIONELL

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

This study is testing a new medication called emicizumab for individuals with Type 3 Von Willebrand Disease, a condition that affects blood clotting. The main goal is to find out if emicizumab is a safe and effective way to prevent bleeding episodes. Some participants will be randomly chosen to receive emicizumab or continue their usual on-demand treatment, while others who already receive regular preventive care will switch to emicizumab and be compared to their own past records. This research aims to offer better treatment options for people living with Type 3 Von Willebrand Disease.

Överblick

Status
Rekrytering
Fas
FAS3
Sponsor
Hoffmann-La Roche
Inskrivningsmål
75
Starta
27 jun 2025
Beräknad slutförande
30 apr 2029

Vad handlar denna studie om?

This study is looking into a new medication called emicizumab for people who have Type 3 Von Willebrand Disease (VWD). VWD is a lifelong condition where your blood doesn't clot properly, leading to a higher risk of bleeding. Type 3 is the most severe form. The researchers want to see how well emicizumab works to prevent bleeding and if it's safe to use.

There are a few different ways people will take part in this study. Some will be chosen by chance to either receive emicizumab or continue with their usual treatment only when they have a bleed (this is called 'on-demand' treatment). Others, who are already having regular preventive treatment for their VWD, will switch to emicizumab. The study will then compare their experiences on emicizumab to their own health information from before they started the new medication.

By comparing emicizumab to current treatments, scientists hope to learn if it can offer a more effective and easier way to manage Type 3 VWD. This could potentially reduce bleeding episodes and improve the quality of life for those living with this condition.

Viktiga punkter

  • This study is for people with Type 3 Von Willebrand Disease.
  • It's testing a new medicine called emicizumab to prevent bleeding.
  • Deltagande innebär regelbundna klinikbesök och hälsokontroller.
  • You might receive emicizumab or continue your usual treatment.
  • Your medical care is not affected if you decide to leave the study.

Vem kan vara berättigad?

To join this study, doctors must have already confirmed that you have Type 3 Von Willebrand Disease. They'll also check your past medical notes to see if you have special proteins in your blood (called VWF inhibitors) and make sure your blood, liver, and kidney functions are healthy enough for the study.

For some parts of the study (Arms A and B), you need to be at least one month old and have used 'on-demand' treatment for VWD, meaning you only treat bleeds as they happen, less than once a week. You also should have had at least two bleeds treated with clotting factor medicine in the 24 weeks before joining (not including period bleeds).

For another part of the study (Arm C), you need to be at least two years old and have been receiving regular preventive treatment for VWD (1-3 times a week) for at least 24 weeks as part of a previous study. You can't have other bleeding disorders, a recent history of stomach bleeding, or a history of bleeding in the brain. If you've had blood clots or are at high risk of them, or have certain other medical conditions, you might not be able to join. You also can't be allergic to certain types of medicines called monoclonal antibodies.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Do I have a confirmed diagnosis of Type 3 Von Willebrand Disease?
  2. Have I used 'on-demand' treatment for VWD, or have I received regular preventive treatment?
  3. Have I had at least two treated bleeds (not period-related) in the last 24 weeks?
  4. Am I generally healthy with no other major bleeding disorders?
  5. Am I free from recent stomach bleeding or a history of bleeding in the brain?
  6. Am I at least 1 month old (or 2 years old for certain groups)?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part, the amount of time and effort involved will depend on which group you're in. Generally, this is a long-term study, and you would have regular visits to the clinic. During these visits, the study team would check your health, ask about any bleeding episodes you've had, and take blood samples. You would receive the study medication, emicizumab, through an injection under your skin, or continue your current treatment as decided by the study. The study team will explain all the specific details of your appointments, tests, and how long you'll be involved.

Potentiella risker och fördelar

Taking part in a study like this might offer the benefit of trying a new treatment that could reduce bleeding episodes and improve your quality of life. However, like all medicines, emicizumab could have side effects, which the study team will explain in detail. There is also the possibility that the new treatment may not work for you, or may not work better than your current treatment. Your safety and well-being are very important, and you would have the right to leave the study at any time, for any reason, without it affecting your medical care.

Platser (29)

  • UC Davis
    Verifierat postnummer
    Sacramento, USA· Rekrytering
  • Universitetet i Florida
    Verifierat postnummer
    Gainesville, USA· Rekrytering
  • University of Kentucky Children's Hospital
    Verifierat postnummer
    Lexington, USA· Rekrytering
  • University of Minnesota Medical Center
    Verifierat postnummer
    Minneapolis, USA· Rekrytering
  • Washington University School of Medicine
    Verifierat postnummer
    St Louis, USA· Rekrytering
  • Virginia Commonwealth University
    Verifierat postnummer
    Richmond, USA· Rekrytering
  • UZ Leuven Gasthuisberg
    Verifierat postnummer
    Leuven, Belgien· Rekrytering
  • Sjukhuset för sjuka barn
    Verifierat postnummer
    Toronto, Kanada· Rekrytering
  • McGill University Health Center
    Verifierat postnummer
    Montreal, Kanada· Rekrytering
  • IPS SURA Industriales Medellín
    Verifierat postnummer
    Medellín, Colombia· Rekrytering
  • Hopital Claude Huriez - CHU Lille
    Verifierat postnummer
    Lille, Frankrike· Rekrytering
  • Groupe Hospitalier Necker Enfants Malades
    Verifierat postnummer
    Paris, Frankrike· Rekrytering

Vanliga frågor

What is Type 3 Von Willebrand Disease?

It's a severe blood clotting disorder where your blood doesn't clot properly, leading to increased bleeding.

Vad är emicizumab?

It's a new medicine being tested to help prevent bleeding in people with Type 3 Von Willebrand Disease.

Will I definitely get emicizumab?

Not necessarily. Depending on which part of the study you're in, you might receive emicizumab or continue with your current usual treatment.

Hur kommer jag att få studiemedicinen?

Emicizumab is given as an injection under the skin.

Kan jag lämna studien om jag ändrar mig?

Yes, you can leave the study at any time for any reason, and it won't affect your future medical care.

Hur du får reda på mer

Reference Study ID Number: WP45338 https://forpatients.roche.com/

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "A Study to Assess the Efficacy and Safety of Emicizumab in P…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.